OneSource Specialty Pharma Q2FY27 Earnings Call Transcript Released
OneSource Specialty Pharma reported strong Q2 FY27 results with revenue up 37% YoY to over ₹5 billion and EBITDA up 53% YoY to 32% margin. New DDC capacity is operational, doubling sterile production days. The company reaffirmed its FY28 outlook of $400 million revenue and $160 million EBITDA.
The strong financial performance, capacity expansion, and reaffirmation of future guidance are significant positive developments that are likely to have a substantial impact on investor sentiment and the company's valuation.
The company reported strong year-on-year and sequential growth in revenue and EBITDA, exceeding expectations. The expansion of production capacity and successful new product launches indicate positive future prospects.
OneSource Specialty Pharma Limited has released the transcript of its earnings call pertaining to the unaudited financial results for the quarter ended September 30, 2026. The call was conducted on October 27, 2026.
During the call, the management reported strong performance for Q2 FY27, marking the third consecutive quarter of sequential growth. Revenue increased by 37% year-on-year and 15% sequentially, exceeding INR 5 billion. EBITDA grew by 53% year-on-year and 32% sequentially, with margins expanding over 400 basis points to 32% for the quarter. This growth was attributed to the additional DDC capacity that came online in Q2, supporting both commercial and MSA revenue. The second cartridge line is now operational, doubling sterile production days, and the third line has completed factory acceptance tests and is ready for qualification, though commercialization might be pushed to early FY28. The company highlighted its end-to-end capabilities, including cartridge filling, assembly, labeling, and packaging, along with cold chain, under one roof, differentiating it globally.
The semaglutide business saw growth, with a partner launching the first generic semaglutide in Saudi Arabia. Dr. Reddy's API has commenced, enabling relaunch in Canada and expansion into other markets. The company also reported multiple new project wins in biologics from new and existing customers, including two end-to-end development to commercialization projects from a US biotech and an additional program for a global animal health company. The biologics RFP funnel is at its highest ever, expected to drive growth beyond FY28. The base business, particularly injectables, is adding new capabilities like prefilled syringes and lyophilization capacity, with new capacity expected from the next quarter.
OneSource reaffirmed its FY28 outlook of $400 million in revenue and $160 million in EBITDA. The company expects the second half of the fiscal year to be stronger than the first. Management also indicated that debt levels are expected to remain under 1.5x EBITDA, with ROCE anticipated in the high 20s by the end of FY28. The expected tax rate is anticipated to continue at current levels through at least Q3 FY28, utilizing brought-forward losses.
What to do with a filing like this
Onesource Specialty Pharma Limited filed this with the NSE as a statutory disclosure, categorised under concall transcript released. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Onesource Specialty Pharma Limited. Read the original for the full detail.